The US Food and Drug Administration has approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children aged two or over. Roche is the developer ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
